4.							
rlease	type a	plus sic	ın (+)	inside	this box	\rightarrow	1 +
		, .					

Please type a plus sign (+) inside this box PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information inform

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

	,		
Sheet	1	of	2

Co	omplete if Known
Application Number	09 868,215
Filing Date	Herewith
First Named Inventor	Monika Junghans
Group Art Unit	1634
Examiner Name	Monika Sheinberg
Attorney Docket Number	WFG/12544

···				U.S. PATENT DOCI	JMENTS	
Examiner Initials*	Cite No.1	U.S. Paten	t Document Kind Code ² (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
						· iguico Appeai
						
	$\neg \uparrow$	· · · · · · · · · · · · · · · · · · ·				
				And the second s		
		w				
					 	

				F	FOR	EIGN PATENT DOCUMENT	S		
Examiner Cite	Cite	<u> </u>	Foreign Patent Do				Date of Publication of	Pages, Columns, Lines,	7
Initials'	als' No.1 Office ³ Number ⁴ Kind Code ⁶ Applicant of Cited Document	Cited Document MM-DD-YYYY	Where Relevant Passages or Relevant Figures Appear	t vants					
U05			EP 0 727 223	A1		Hisamitsu Pharmaceutical	08-21-1996		
						The state of the s			
									—
									┼
									-
									†
					\dashv				
				Į.					

Examiner Signature	Date Considered 1/10/63
*EYAMINED: Initial if reference	/

reference considered, whether of not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

,b	9 2 2 0 0 8 2 15
Please type a plus sign (+) inside this box →	PTO/SB/08B (08-00) Approved for use through 10/31/2002. OMB 0651-0031
Under the Paperwork Reduction Act of 1995, no persons are required to resp	U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE cond to a collection of information unless it contains a valid OMB control number.
Substitute for form 1449B/PTO	Complete if Known
	Application Number (10) (14) (1)

Substitu	ute for form 1449E	3/PTO		Cç	omplete if Known	9	Λ	61 IN I
INIE		ON DIC	CLOSURE	Application Number	09 1868, 215			WIN .
				Filing Date	Herewith			
STATEMENT BY APPLICANT				First Named Inventor	Monika Junghans			
				Group Art Unit	1634			
	(use as ma	ny sheets as	necessary)	Examiner Name	Moniter Sheinberg			
Sheet	2	of	2	Attorney Docket Number	WFG/12544			
			-					

	OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS							
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T2					
NBS		LI, S. UND HUANG, L.: "In vivo gene transfer via intravenous administration of cationic lipid-protamine-DNS (LPD) complexes", GENE THERAPY, Bd. 4, 1997, Seiten 891-900, XP000886074.						
NBS		WOLFERT, M.A. UND SEYMOUR, L.W.: "Atomic force microscopic analysis of the influence of the molecular weight of poly (L) lysine on the size of polyelectrolyte complexes formed with DNA", GENE THERAPY, Bd. 3, 1996, Seiten 269-73, XP000886345.						
MS	>	WIENHUES, U. ET AL.: "A novel method for transfection and expression of reconstituted DNA-protein complexes in eukaryotic cells", DNA, Bd. 6, 1987 Seiten 81-9, XP000560129.						
MBS		WO 93/04701, Date of Publication: 18 March 1993, TARGETED DELIVERY OF POLY OR OLIGONUCLEOTIDES TO CELLS.						
MBS		WO 95/25809, Date of Publication: 28 September 1995, COMPACTED NUCLEIC ACIDS AND THEIR DELIVERY TO CELLS.						
MBS		WO 98/06437, Date of Publication: 19 February 1998, COMPOSITIONS AND METHODS FOR POLYNUCLEOTIDE DELIVERY.						

Examiner	0 '0	Date	.1 . 1 -
Signature		l I	110103
Cognatare		Considered	{ ' / =

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.